Effect on Intraocular Pressure of Switching from Latanoprost and Travoprost Monotherapy to Timolol Fixed Combinations in Patients with Normal-Tension Glaucoma

Igarashi, Ryoko; Togano, Tetsuya; Sakaue, Yuta; Yoshino, Takaiko; Ueda, Jun; Fukuchi, Takeo

doi:10.1155/2014/720385

Cited by 5 publications

(3 citation statements)

References 21 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PGA therapy reduced IOP by more than 20% from pretreatment values even in patients with NTG [ 24 , 25 ]. The 10% reduction observed in this study after switching to Duotrav is similar to those reported previously in NTG populations [ 26 , 27 ]. The absolute reduction of about 1.5 mmHg associated with switching to Duotrav seems to represent a meaningful treatment benefit, considering the findings from the Early Manifest Glaucoma Trial where every 1 mmHg of IOP reduction has patient benefit [ 21 ].…”

Section: Discussionsupporting

confidence: 91%

Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study

et al. 2015

View full text Add to dashboard Cite

IntroductionThe efficacy of lowering intraocular pressure (IOP) and safety of switching to travoprost/timolol fixed combination ophthalmic solution (Duotrav®, Alcon Laboratories, Inc., Fort Worth, TX, USA) in patients with primary open-angle glaucoma, normal tension glaucoma or ocular hypertension undergoing prostaglandin analog (PGA) monotherapy was investigated.MethodsPatients treated with travoprost, latanoprost, tafluprost, or bimatoprost for ≥3 months and requiring additional medication were switched to Duotrav without washout. Baseline IOP was calculated from measurements at two visits during PGA monotherapy. IOP reductions at 4, 8, and 12 weeks after switching to Duotrav and adverse events were assessed.ResultsOf 162 patients enrolled, 157 patients (96.9%) with ≥4 weeks of follow-up after switching to Duotrav were analyzed. The mean IOP decreased significantly (baseline = 16.3 ± 3.1 mmHg; 4 weeks = 14.6 ± 3.1 mmHg, 8 weeks = 14.7 ± 3.3 mmHg, 12 weeks = 14.6 ± 3.2 mmHg; all P < 0.0001). When study eyes were divided into three groups according to baseline IOP (≥19 mmHg: 33 eyes, 21.0%; ≥15 to <19 mmHg: 78 eyes, 49.7%; <15 mmHg: 46 eyes, 29.3%), all groups showed significant IOP reductions (P = 0.0324 ~ P < 0.0001) after switching to Duotrav. Twenty-seven of 166 patients (16.3%) in the safety analysis experienced adverse events and 26/166 patients (15.7%) experienced adverse events, for which a relationship to Duotrav could not be ruled out. Adverse events in five patients led to treatment discontinuation (eye pruritus; eye irritation; increased blood pressure and rash; increased blurred vision; deepening of the eyelid sulcus and blepharoptosis). Twelve weeks after treatment switching, eyelash changes, blepharal pigmentation and deepening of the eyelid sulcus occurred in 42 (26.8%), 29 (18.5%), and 13 (8.3%) cases, respectively, among 157 patients with follow-up. There was no significant worsening from baseline for superficial punctate keratopathy (SPK) or conjunctival hyperemia after switching (SPK score: baseline = 0.58 ± 1.31; 12 weeks = 0.92 ± 1.76, P = 0.1819; conjunctival hyperemia score: baseline = 0.41 ± 0.64; 12 weeks = 0.49 ± 0.63, P = 0.3774).ConclusionOur findings confirm that switching to Duotrav® in PGA monotherapy patients shows IOP-lowering effect with minimal safety concerns.FundingJapan Association of Health Service and Alcon Japan. Ltd.Trial registrationUMIN Clinical Trials Registry identifier, UMIN000007028.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-015-0246-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 91%

Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Since 1996, latanoprost has been approved for clinical use in the United States and Europe and was introduced as the first prostaglandin analog in Korea. In Japan, prostaglandin analogs have become the first-line treatment for NTG because of their ability to reduce IOP [ 5 ]. As in Japan, a survey of the Korean Glaucoma Society resulted in agreement that the first-line treatment for NTG is a prostaglandin analog, especially latanoprost.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Effects of Dorzolamide/Timolol Fixed Combination versus Latanoprost on Intraocular Pressure and Ocular Perfusion Pressure in Patients with Normal-Tension Glaucoma: A Randomized, Crossover Clinical Trial

Lee

2016

PLoS ONE

View full text Add to dashboard Cite

BackgroudTo assess the noninferiority of a dorzolamide-timolol fixed combination (DTFC) versus latanoprost in terms of intraocular pressure (IOP) and to compare blood pressure (BP), ocular perfusion pressure (OPP) and diastolic ocular perfusion pressure (DOPP) between the latanoprost and DTFC groups in patients with normal-tension glaucoma (NTG).MethodsProspective, interventional, randomized, single-blinded, crossover design study. Patients with newly diagnosed NTG that had not been treated with a glaucoma medication in the most recent 2 months were recruited. In total, 44 patients with NTG were randomly allocated to one of two groups. Patients in group A were treated with DTFC, lubricant, and latanoprost for 4 weeks each, whereas patients in group B were treated with latanoprost, lubricant, and DTFC for 4 weeks each. Patients were examined on day 1 (without medication), week 4 (under medication), week 8 (without medication), and week 12 (under medication). At weeks 4 and 12, diurnal IOP, systolic and diastolic BP, and OPP were measured at 8:00 AM, 10:00 AM, 12:00 PM, 4:00 PM, and 8:00 PM.ResultsBaseline demographic characteristics showed no difference in terms of age, sex, central corneal thickness, spherical equivalent, or stage of glaucoma between the groups. The between-group difference was -0.19 ± 0.18 mmHg (mean ± SE, upper bound of one-sided 95% CI, 0.12). Diurnal IOP showed no difference between the groups with an average IOP reduction of 13.1% using latanoprost and 12.3% using DTFC. Diurnal systolic and diastolic BP were lower in the DTFC group than the latanoprost group; however, the difference between the groups was not statistically significant. Diurnal OPP and DOPP also showed no statistically significant difference between the groups.ConclusionsIOP lowering efficacy of DTFC was noninferior to that of latanoprost in newly diagnosed NTG patients. There was no difference in BP, OPP, or DOPP between the latanoprost and DTFC groups. This prospective, randomized, single-blinded, crossover study demonstrated the noninferiority of DTFC versus latanoprost in terms of IOP in patients with NTG.Trial RegistrationClinicalTrials.gov NCT01175902

show abstract

“…В метаанализе Aptel F. et al (2012) ФК латанопрост/тимолол (ФКЛТ) оказывала более выраженное гипотензивное действие в сравнении с монотерапией латанопростом, подтвержден меньший риск развития НЯ [15]. Аналогичные результаты получены Igarashi R. et al (2014) [16].…”

Section: результаты клинических исследованийunclassified

Фиксированные Комбинированные Препараты В Лечении Пациентов С Первичной Открытоугольной Глаукомой

Джумова¹,

Марченко²,

Чекина³

et al. 2021

Офтальмология. Восточная Европа

View full text Add to dashboard Cite

Эффективной и доказанной стратегией для сохранения зрительных функций и качества жизни пациента является воздействие на внутриглазное давление (ВГД), которое должно быть снижено до целевого уровня. В ряде случаев достижение целевого уровня возможно при одновременном применении нескольких топических гипотензивных средств. Предпочтительно применение фиксированных комбинированных препаратов. За последние десятилетия были разработаны и внедрены в практику несколько оригинальных гипотензивных препаратов различного принципа действия и их дженериков, применяемых для лечения пациентов с глаукомой. Возможность взаимозаменяемости оригинального препарата аналогом является актуальной для каждого офтальмолога. В данном обзоре обобщены данные о простагландиновых и непростагландиновых фиксированных комбинированных препаратах, их дженериках, преимуществах бесконсервантных препаратов, гипотензивном эффекте, безопасности и переносимости в сравнении с другими гипотензивными средствами и их комбинациями. Reduction of intraocular pressure (IOP) is an effective strategy for preserving visual functions and quality of life in patients with primary open-angle glaucoma (POAG). In some cases, achieving the target level of IOP is possible with the use of several topical antihypertensive agents. The use of fixed combinations of drugs is preferable. Over the past decades, several original antihypertensive drugs and their generics used to treat patients with glaucoma have been developed and put into practice. In this review, we will try to summarize the data on fixed prostaglandin and non-prostaglandin combined drugs, generics, the advantages of preservative-free drugs, their hypotensive effect in comparison with other antihypertensive agents and their combinations.

show abstract

Effect on Intraocular Pressure of Switching from Latanoprost and Travoprost Monotherapy to Timolol Fixed Combinations in Patients with Normal-Tension Glaucoma

Cited by 5 publications

References 21 publications

Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study

Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study

Comparison of the Effects of Dorzolamide/Timolol Fixed Combination versus Latanoprost on Intraocular Pressure and Ocular Perfusion Pressure in Patients with Normal-Tension Glaucoma: A Randomized, Crossover Clinical Trial

Фиксированные Комбинированные Препараты В Лечении Пациентов С Первичной Открытоугольной Глаукомой

Contact Info

Product

Resources

About